Publication : 17/09/2020
Description: Radiotherapy is one of the main treatments for solid tumors. Severe late radiation-induced toxicity of the surrounding normal tissues occurs in 5% to 10% of patients following radiotherapy. The radiation-induced lymphocyte apoptosis assay developed to predict late radiation-induced toxicity in patients has demonstrated to be significantly associated with toxicities. However, the molecular mechanism explaining the link between the lymphocyte apoptosis rate and the development of late toxicity is still unknown. It is well established that the acid sphingomyelinase/ceramide pathway is involved in radiation-induced apoptosis, more particularly in endothelial cells. We have started to look at this pathway in peripheral blood mononuclear cells (PBMC) in cancer patients. We observed ceramide expression in response to radiation in patients’ samples and we were able to identify an increase in acid sphingomyelinase activity at 8 Gy. This project proposes to study the ceramide pathways in PBMC responsiveness to ionizing radiation in cancer patients and the consequences on apoptosis, ROS and inflammation.
The goal of this project is to have a better understanding on the correlation between radiation-induced late toxicity and apoptosis and to help improve the life quality of the patients.
Publication : 02/09/2020
The NanoTumor consortium is a French national multi-disciplinary workforce that aims to study cancer initiation and progression at molecular and subcellular level, by combining cutting-edge technologies and expertise in electron and fluorescence 2D-3D imaging, spatial transcriptomics and mass-spectrometry, micropatterning and microfluidics/biomechanics in various cellular and animal models, anti-intrabody/PPI engineering, and high-throughput screening. It will explore several children and adults’ cancers characteristics from the structure of underlying molecular complexes, spatio-temporal genes and proteins expression patterns, all the way up to subcellular organization, tissues morphology/rheology, and ultimately drug design and screening.
To support the research program of WP3, a postdoc/engineer will be initially hired for 18 months with the objective of securing 18 additional months. The postdoc/engineer will be in charge of optimizing the experimental protocols required during the project, in particular immunochemistry, cell culture, live cell imaging techniques, and biochemistry. The postdoc/engineer will be also in charge of the formation of students (Masters, PhD) to these experimental approaches. Previous experience in NGS, proteomics, HTS, protein engineering, and/or bioinformatics would be a strong asset. The position will be located at the IRCM in Montpellier, but will require personal flexibility since the postdoc/engineer may be involved in experiments in all the laboratories of the consortium (stays from days to months).
Publication : 21/08/20
M2-Internship, 6 to 8 month
Project : Identification of novel therapeutic targets in liver metastasized colon adenocarcinoma by direct selection of antibody phage libraries on patient samples
(Identification de nouvelles cibles thérapeutiques dans l’adénocarcinome du colon métastasé au foie par criblage direct de banques de phages anticorps sur échantillons de patients)
Workplace : Microenvironment and Therapy Resistance Team (Dr Andrei Turtoi), Institut de Recherche en Cancérologie de Montpellier, 208 Avenue des Apothicaires F-34298 Montpellier Cedex 5, France
Funding: Labex MabImprove, Université de Tours et Montpellier,
Keywords: Liver metastasis, colon cancer, therapeutic target, biomarker, antibody phage display, immunotherapy.
Contact: Marie-Alix Poul (AT INSERM FR)
Publication : 21/08/20
Nous recherchons un(e) TS ou AI pour rejoindre un projet multiéquipe. Le poste est à pourvoir pour 1 an dans l'équipe "Criblage fonctionnel et ciblage du cancer" de l'IRCM.
Le candidat bac+2 devra conduire, sous la responsabilité d'un postdoc, des expériences de clonage, production, purification et modifications chimiques de protéines recombinantes (cultures cellulaires, dosages biologiques ou biochimiques, techniques immunologiques, biochimiques et de biologie moléculaire ...)
Merci d'envoyer CV et lettre de motivation à Eve COMBES ( AT INSERM . FR ) avant fin août 2020.
Situé dans le Parc Euromédecine, l'Institut de Recherche en Cancérologie de Montpellier (U1194) est localisé sur le Campus Val d'Aurelle (ICM, Institut régional du Cancer Montpellier / Val d'Aurelle).
Centre de Recherche U1194 soutenu par l'Inserm, l'Université de Montpellier et l'Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de
